Rheumatology, University Hospital Ghent, Ghent, Belgium
VIB Center for Inflammation Research, Ghent, Belgium.
RMD Open. 2020 May;6(1). doi: 10.1136/rmdopen-2019-001136.
Peripheral spondyloarthritis (pSpA) refers to a number of seemingly different spondyloarthritis subsets in which psoriatic arthritis (PsA) is the most common, and symptoms of arthritis, enthesitis or dactylitis predominate the clinical presentation. Although formal classification criteria for pSpA have been introduced in 2011, only a minority of epidemiological and clinical studies addressed this clinical entity as a separate disease. Moreover, research on outcome measures and treatment modalities in pSpA has been mainly focused on PsA. Subsequently, all biological treatments are off-label in patients with non-psoriatic pSpA. Its neglected status has important implications for clinical practice since the emerging group of early-diagnosed non-psoriatic pSpA patients remains poorly characterised and lacks specific treatment recommendations. This review summarises what is currently known regarding pSpA in terms of epidemiology, clinical presentation, diagnosis and therapeutic approach.
外周型脊柱关节炎(pSpA)是一组看似不同的脊柱关节炎亚类,其中最常见的是银屑病关节炎(PsA),关节炎、附着点炎或指(趾)炎的症状是其主要临床表现。尽管在 2011 年已经引入了外周型脊柱关节炎的正式分类标准,但只有少数流行病学和临床研究将这一临床实体作为一种单独的疾病来探讨。此外,pSpA 中结局指标和治疗方法的研究主要集中在 PsA 上。因此,所有生物治疗在非银屑病性 pSpA 患者中均属于超适应证用药。由于早期诊断的非银屑病性 pSpA 患者这一新兴群体特征仍不明确,且缺乏特定的治疗建议,因此该病被忽视的状况对临床实践具有重要意义。本文综述了目前已知的关于 pSpA 的流行病学、临床表现、诊断和治疗方法方面的信息。